CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Resource Type
Article
Authors
Coombs, Catherine C. ; Pagel, John M. ; Shah, Nirav N. ; Lamanna, Nicole ; Munir, Talha ; Lech-Maranda, Ewa ; Eyre, Toby A. ; Woyach, Jennifer A. ; Wierda, William G. ; Cheah, Chan Y. ; Cohen, Jonathon B. ; Roeker, Lindsey E. ; Patel, Manish R. ; Fakhri, Bita ; Barve, Minal A. ; Tam, Constantine S. ; Lewis, David ; Gerson, James N. ; Alencar, Alvaro ; Ujjani, Chaitra ; Flinn, Ian ; Sundaram, Suchitra ; Ma, Shuo ; Jagadeesh, Deepa ; Rhodes, Joanna ; Taylor, Justin ; Abdel-Wahab, Omar ; Ghia, Paolo ; Schuster, Stephen J. ; Wang, Denise ; Nair, Binoj ; Zhu, Edward ; Tsai, Donald E. ; Davids, Matthew S. ; Brown, Jennifer R. ; Jurczak, Wojciech ; Mato, Anthony R.
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S268-S269
Subject
Language
ISSN
2152-2650